Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System™ – medicines that have the potential to transform the prevention and management of serious chronic diseases.

They focus their efforts on diseases that are prevalent and poorly controlled, and that are growing at an epidemic rate. This gives them a dual focus in preventive and therapeutic medicine. Their near-term goal is to deliver a game-changing new level of glycemic control for a vast number of patients with type 2 diabetes. Making a real difference in this area where little or no progress has been made in more than a decade for the majority of patients – despite numerous new pills and injections – is their future and their passion. Their longer-term goal is to expand their Medici Drug Delivery System further into diabetes/obesity treatment and its prevention, and their critical new initiative for improved global HIV prevention through a landmark collaboration with the Bill and Melinda Gates Foundation.

Their Purpose

To unleash life’s possibilities with disruptively innovative medicines — each proven to raise the standard of care, improves lives, and to provide attractive value creation and business results. They live bytheir core values striving to earn and preserve the trust, respect and admiration of all their stakeholders — including their own people by providing a differentiated and fulfilling place to work.

Their Values

Their values form the core of who they are and how they differentiate theirselves. They shape their actions in business and their interactions with others. Their values place “winning for patients” at the center of everything they do. Their values are not just words on a website. What distinguishes their people is that they live their values every day — at all levels and in all aspects of their Company.

THEIR STRATEGY

At Intarcia, through the passion and commitment of their employees, they seek to leverage their technologies in drug development and delivery to provide improved therapeutic outcomes for patients and to help patients achieve a better quality of life.

One of the biggest problems in the treatment of chronic disease is that at least half of patients lack effective control of their condition due to the sub-optimal effectiveness of their medication in the ‘real-world’ circumstances in which they must be taken: patients living at home who are on their own to follow the prescribing instructions for their medications. Unfortunately, after just three-to-six months, the majority of patients with chronic conditions stop taking their pills and injections as prescribed by their doctor. They aim to address this widespread and serious problem in chronic disease by introducing a new way to deliver therapies continuously and consistently for very extended periods of time. By doing so, their advanced drug delivery system has the potential to deliver game-changing improvement in medication adherence over time, promising to break the long-standing and costly barrier to greater efficacy and better long-term outcomes in chronic disease management.

Their novel technology platform, the Medici Drug Delivery System™, is a proprietary subcutaneous delivery system comprised of three unique technologies:

• - A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more
• - A matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication
• - A placement technology including proprietary tools designed to provide an optimal user experience

Once a drug is approved, a trained healthcare professional can place the small device in an in-office procedure. Once in place under the skin, water from the extracellular fluid enters the pump device at one end – by diffusing through a semi-permeable membrane directly into an osmotic engine – that expands to drive a piston at a controlled rate. This allows the drug within the pump to be released in a steady, consistent fashion at the other end of the device. Each osmotic mini-pump is designed to hold an appropriate volume of drug to treat a patient for up to a full year.

Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic, serious disorders such as diabetes, obesity, autoimmune, and other serious diseases.

Developing Products with Significant Market Potential

Intarcia strives to develop product candidates with a demonstrated potential to deliver significant therapeutic improvements over existing therapies. They focus on therapies that address significant unmet medical needs and represent large commercial opportunities. The therapies they are developing:

• - Are based on promising therapeutic classes with proven clinical safety and activity;
• - Hold potential to represent significant improvements over the established standards of care;
• - May qualify for accelerated development and regulatory pathways; and
• - Create proprietary product candidates, securing or extending exclusivity.

By targeting product candidates from proven therapeutic classes and existing safety and clinical data, their development approach allows them to mitigate risks while reducing the cost and time required for developing products. If they are able to complete product development with fewer clinical trials than are required for a new therapeutic, they may have lower development costs and shorter timelines. By delivering these product candidates facilitated by Intarcia's Medici Drug Delivery System™, they strive to deliver therapy with a truly optimized therapeutic index.